Drug Approval | June 29, 2025
Briefs: Neuland Laboratories and Granules India
Granules India receives 1 observation from USFDA for Chantilly facility
Granules India receives 1 observation from USFDA for Chantilly facility
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
The FDA issued Form 483 with one observation related to building and facility management
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
Neuland Laboratories has reported total income of Rs. 390.36 crores during the period ended March 31, 2024
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Cipla has received 8 inspectional observations in Form 483
He brings over 30 years of experience across various organizations such as Asian Paints PPG, Berger Paints, Tata Steel, among others
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Subscribe To Our Newsletter & Stay Updated
